A Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer
What is the purpose of this trial?
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
- Trial withYale Cancer Center
- Start Date06/23/2020
- End Date10/31/2023
- Last Updated07/15/2021
- Study HIC#2000023841